Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04955275 · ClinicalTrials.gov registry record · NA

The Efficacy of a Remote Cognitive Remediation Therapy (CRT) Program on Parkinson's Disease

A NA study of Parkinson Disease, sponsored by New York Institute of Technology.

Completed
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT04955275: Completed NA study of Parkinson Disease, sponsored by New York Institute of Technology.

NCT04955275 is a NA study of Parkinson Disease that has completed, run by New York Institute of Technology. The registered enrollment target is 25 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04955275, a NA study of Parkinson Disease, has completed, sponsored by New York Institute of Technology.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

Purpose/Goal: To determine if a remote computerized cognitive remediation program (CRT) can stabilize or improve cognitive functioning in a group of patients from the New York Institute of Technology Academic Health Care Center with Parkinson's disease (PD) after three months of intervention. Hypothesis: Patients with PD who present with current cognitive deficits will show improvement in such deficits after three months of participation in a remotely supervised structured Cognitive Remediation Therapy Program (CRT) compared to control subjects with PD who receive treatment as usual. Research design: Pilot study. Prospective randomized treatment and control comparison pre-post study.

Primary Outcome

A brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory.

Conditions Studied

Interventions

  • OTHER Cognitive Remediation Therapy Program (BrainHQ)

Study Locations (1)

New York

  • New York Institute of Technology - Old Westbury

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2021-06-01
Est. Completion 2022-04-01
Phase NA
New York Institute of Technology

49 total trials

What the finished NCT04955275 record still lists

NCT04955275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Cognitive Remediation Therapy Program (BrainHQ) is the first listed.

NCT04955275 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04955275 about?

NCT04955275 is a clinical study titled "The Efficacy of a Remote Cognitive Remediation Therapy (CRT) Program on Parkinson's Disease". Purpose/Goal: To determine if a remote computerized cognitive remediation program (CRT) can stabilize or improve cognitive functioning in a group of patients from the New York Institute of Technology Academic Health Care Center with Parkinson's disease (PD) after three months of intervention. Hypot...

What is the current status of trial NCT04955275?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2021-06-01. Estimated completion is 2022-04-01.

What conditions does trial NCT04955275 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT04955275?

The interventions under investigation include: Cognitive Remediation Therapy Program (BrainHQ) (OTHER).

Who is sponsoring clinical trial NCT04955275?

This trial is sponsored by New York Institute of Technology, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04955275 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04955275's enrollment target sits among peer trials

25 225th of 297 higher than 67 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04955275, the US trial registry maintained by the National Library of Medicine. NCT04955275 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.